1. Activation of dendritic cells by local ablation of hepatocellular carcinoma.
- Author
-
Ali MY, Grimm CF, Ritter M, Mohr L, Allgaier HP, Weth R, Bocher WO, Endrulat K, Blum HE, and Geissler M
- Subjects
- CD11c Antigen metabolism, Carcinoma, Hepatocellular pathology, Cell Separation, Dendritic Cells cytology, Flow Cytometry, Humans, Immunotherapy, Interleukin-1 blood, Interleukin-12 blood, Interleukin-3 Receptor alpha Subunit, Liver Neoplasms pathology, Lymphocyte Activation, Neoplasm Metastasis, Neoplasm Recurrence, Local prevention & control, Receptors, Interleukin-3 metabolism, T-Lymphocytes cytology, T-Lymphocytes immunology, Tumor Necrosis Factor-alpha metabolism, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular therapy, Catheter Ablation, Dendritic Cells metabolism, Liver Neoplasms immunology, Liver Neoplasms therapy
- Abstract
Background/aims: Local ablation methods are an effective treatment for hepatocellular carcinoma (HCC). The rate of recurrence or development of intra-hepatic metastases may be lowered by antitumoral immune responses. Since HCCs are in general only weakly immunogenic, cell injury induced by local tumor ablation (PEI/RFTA) may increase HCC immunogenicity and may release endogenous adjuvants that activate dendritic cells (DC). The aim of the study, therefore, was the analysis whether PEI or RFTA induced injury results in an adjuvant effect for immune responses to HCCs., Methods: Eight HCC patients were treated with PEI or RFTA and serially analyzed for 4 weeks. Plasmocytoid (PDC) and myeloid dendritic cells (MDC) were analyzed directly ex vivo and in vitro using FACS and proliferation assays., Results: HCC ablation induced a functional transient activation of MDC but not of PDC associated with increased serum levels of TNF-alpha and IL-1beta., Conclusions: These findings suggest that the combination of PEI or RFTA and active antigen specific immunotherapeutic approaches using DCs is a promising approach for the induction of sustained antitumoral immune responses aiming at the reduction of tumor recurrence and metastases in HCC patients.
- Published
- 2005
- Full Text
- View/download PDF